Molecular Neurobiology

, Volume 50, Issue 1, pp 119–129 | Cite as

Cellular Membrane Fluidity in Amyloid Precursor Protein Processing

  • Xiaoguang Yang
  • Grace Y. Sun
  • Gunter P. Eckert
  • James C-M. Lee


The senile plaque is a pathologic hallmark of Alzheimer's disease (AD). Amyloid-β peptide (Aβ), the main constituent of senile plaques, is neurotoxic especially in its oligomeric form. Aβ is derived from the sequential cleavage of amyloid precursor protein (APP) by β- and γ-secretases in the amyloidogenic pathway. Alternatively, APP can be cleaved by α-secretases within the Aβ domain to produce neurotrophic and neuroprotective α-secretase-cleaved soluble APP (sAPPα) in the nonamyloidogenic pathway. Since APP and α-, β-, and γ-secretases are membrane proteins, APP processing should be highly dependent on the membrane composition and the biophysical properties of cellular membrane. In this review, we discuss the role of the biophysical properties of cellular membrane in APP processing, especially the effects of phospholipases A2 (PLA2s), fatty acids, cholesterol, and Aβ on membrane fluidity in relation to their effects on APP processing.


APP Alzheimer's disease Cellular membrane 


  1. 1.
    Larson ME, Lesne SE (2012) Soluble Abeta oligomer production and toxicity. J Neurochem 120(Suppl 1):125–139PubMedPubMedCentralGoogle Scholar
  2. 2.
    Vassar R (2004) BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci 23:105–114PubMedGoogle Scholar
  3. 3.
    Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med 2:a006270PubMedPubMedCentralGoogle Scholar
  4. 4.
    Thornton E, Vink R, Blumbergs PC, Van Den Heuvel C (2006) Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res 1094:38–46PubMedGoogle Scholar
  5. 5.
    Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G (2007) Mechanisms of disease: new therapeutic strategies for Alzheimer's disease—targeting APP processing in lipid rafts. Nat Clin Pract Neurol 3:374–382PubMedPubMedCentralGoogle Scholar
  6. 6.
    Winkler E, Kamp F, Scheuring J, Ebke A, Fukumori A, Steiner H (2012) Generation of Alzheimer disease-associated Abeta42/43 by gamma-secretase can directly be inhibited by modulation of membrane thickness. J Biol Chem 287:21326–21334PubMedPubMedCentralGoogle Scholar
  7. 7.
    Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ (1993) Beta-amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 268:3021–3024PubMedGoogle Scholar
  8. 8.
    Koo EH, Squazzo SL (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 269:17386–17389PubMedGoogle Scholar
  9. 9.
    Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ (2003) Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. Proc Natl Acad Sci U S A 100:11735–11740PubMedPubMedCentralGoogle Scholar
  10. 10.
    Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160:113–123PubMedPubMedCentralGoogle Scholar
  11. 11.
    Kaether C, Haass C (2004) A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation. J Cell Biol 167:809–812PubMedPubMedCentralGoogle Scholar
  12. 12.
    Marlow L, Cain M, Pappolla MA, Sambamurti K (2003) Beta-secretase processing of the Alzheimer's amyloid protein precursor (APP). J Mol Neurosci 20:233–239PubMedGoogle Scholar
  13. 13.
    Tun H, Marlow L, Pinnix I, Kinsey R, Sambamurti K (2002) Lipid rafts play an important role in A beta biogenesis by regulating the beta-secretase pathway. J Mol Neurosci 19:31–35PubMedGoogle Scholar
  14. 14.
    Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC et al (2004) Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem 279:44945–44954PubMedPubMedCentralGoogle Scholar
  15. 15.
    Reid PC, Urano Y, Kodama T, Hamakubo T (2007) Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J Cell Mol Med 11:383–392PubMedGoogle Scholar
  16. 16.
    Alessandri JM, Guesnet P, Vancassel S, Astorg P, Denis I, Langelier B, Aid S et al (2004) Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod Nutr Dev 44:509–538PubMedGoogle Scholar
  17. 17.
    Liu MS, Ghosh S, Yang Y (1983) Change in membrane lipid fluidity induced by phospholipase A activation: a mechanism of endotoxic shock. Life Sci 33:1995–2002PubMedGoogle Scholar
  18. 18.
    Schaeffer EL, Bassi F Jr, Gattaz WF (2005) Inhibition of phospholipase A2 activity reduces membrane fluidity in rat hippocampus. J Neural Transm 112:641–647PubMedGoogle Scholar
  19. 19.
    Hibbeln JR, Umhau JC, George DT, Shoaf SE, Linnoila M, Salem N Jr (2000) Plasma total cholesterol concentrations do not predict cerebrospinal fluid neurotransmitter metabolites: implications for the biophysical role of highly unsaturated fatty acids. Am J Clin Nutr 71:331S–338SPubMedGoogle Scholar
  20. 20.
    Sinclair AJ, Begg D, Mathai M, Weisinger RS (2007) Omega 3 fatty acids and the brain: review of studies in depression. Asia Pac J Clin Nutr 16(Suppl 1):391–397PubMedGoogle Scholar
  21. 21.
    Yang X, Sheng W, Sun GY, Lee JC (2011) Effects of fatty acid unsaturation numbers on membrane fluidity and alpha-secretase-dependent amyloid precursor protein processing. Neurochem Int 58:321–329PubMedPubMedCentralGoogle Scholar
  22. 22.
    Peters I, Igbavboa U, Schutt T, Haidari S, Hartig U, Rosello X, Bottner S et al (2009) The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochim Biophys Acta 1788:964–972PubMedPubMedCentralGoogle Scholar
  23. 23.
    Giuffrida ML, Tomasello F, Caraci F, Chiechio S, Nicoletti F, Copani A (2012) Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease. Mol Neurobiol 46:605–613PubMedGoogle Scholar
  24. 24.
    Demuro A, Parker I, Stutzmann GE (2010) Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 285:12463–12468PubMedPubMedCentralGoogle Scholar
  25. 25.
    Yamin G (2009) NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. J Neurosci Res 87:1729–1736PubMedGoogle Scholar
  26. 26.
    Xie CW (2004) Calcium-regulated signaling pathways: role in amyloid beta-induced synaptic dysfunction. Neuromol Med 6:53–64Google Scholar
  27. 27.
    Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G (2011) Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 111:6130–6185PubMedPubMedCentralGoogle Scholar
  28. 28.
    Zhou L, Nilsson A (2001) Sources of eicosanoid precursor fatty acid pools in tissues. J Lipid Res 42:1521–1542PubMedGoogle Scholar
  29. 29.
    Moses GS, Jensen MD, Lue LF, Walker DG, Sun AY, Simonyi A, Sun GY (2006) Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J Neuroinflammation 3:28PubMedPubMedCentralGoogle Scholar
  30. 30.
    Farooqui AA, Ong WY, Horrocks LA (2006) Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 58:591–620PubMedGoogle Scholar
  31. 31.
    Sun GY, Horrocks LA, Farooqui AA (2007) The roles of NADPH oxidase and phospholipases A2 in oxidative and inflammatory responses in neurodegenerative diseases. J Neurochem 103:1–16PubMedGoogle Scholar
  32. 32.
    Yedgar S, Cohen Y, Shoseyov D (2006) Control of phospholipase A2 activities for the treatment of inflammatory conditions. Biochim Biophys Acta 1761:1373–1382PubMedGoogle Scholar
  33. 33.
    Sun GY, Xu J, Jensen MD, Yu S, Wood WG, Gonzalez FA, Simonyi A et al (2005) Phospholipase A2 in astrocytes: responses to oxidative stress, inflammation, and G protein-coupled receptor agonists. Mol Neurobiol 31:27–41PubMedGoogle Scholar
  34. 34.
    Desbene C, Malaplate-Armand C, Youssef I, Garcia P, Stenger C, Sauvee M, Fischer N et al (2012) Critical role of cPLA2 in Abeta oligomer-induced neurodegeneration and memory deficit. Neurobiol Aging 33(1123):e1117–e1129Google Scholar
  35. 35.
    Sun GY, He Y, Chuang DY, Lee JC, Gu Z, Simonyi A, Sun AY (2012) Integrating cytosolic phospholipase A(2) with oxidative/nitrosative signaling pathways in neurons: a novel therapeutic strategy for AD. Mol Neurobiol 46:85–95PubMedPubMedCentralGoogle Scholar
  36. 36.
    Gentile MT, Reccia MG, Sorrentino PP, Vitale E, Sorrentino G, Puca AA, Colucci-D'Amato L (2012) Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis. Mol Neurobiol 45:596–604PubMedGoogle Scholar
  37. 37.
    Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA (1996) Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol Dis 3:51–63PubMedGoogle Scholar
  38. 38.
    Stephenson D, Rash K, Smalstig B, Roberts E, Johnstone E, Sharp J, Panetta J et al (1999) Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. Glia 27:110–128PubMedGoogle Scholar
  39. 39.
    Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ (2002) Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosc Res 70:462–473Google Scholar
  40. 40.
    Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cisse M et al (2008) Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11:1311–1318PubMedPubMedCentralGoogle Scholar
  41. 41.
    Kriem B, Sponne I, Fifre A, Malaplate-Armand C, Lozac'h-Pillot K, Koziel V, Yen-Potin FT et al (2005) Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide. Faseb J 19:85–87PubMedGoogle Scholar
  42. 42.
    Yang X, Askarova S, Sheng W, Chen JK, Sun AY, Sun GY, Yao G et al (2010) Low energy laser light (632.8 nm) suppresses amyloid-beta peptide-induced oxidative and inflammatory responses in astrocytes. Neuroscience 171:859–868PubMedPubMedCentralGoogle Scholar
  43. 43.
    Zhu D, Lai Y, Shelat PB, Hu C, Sun GY, Lee JC (2006) Phospholipases A2 mediate amyloid-beta peptide-induced mitochondrial dysfunction. J Neurosci 26:11111–11119PubMedGoogle Scholar
  44. 44.
    Chalimoniuk M, Stolecka A, Cakala M, Hauptmann S, Schulz K, Lipka U, Leuner K et al (2007) Amyloid beta enhances cytosolic phospholipase A2 level and arachidonic acid release via nitric oxide in APP-transfected PC12 cells. Acta Biochim Pol 54:611–623PubMedGoogle Scholar
  45. 45.
    Askarova S, Yang X, Sheng W, Sun GY, Lee JC (2011) Role of Abeta-receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase A(2) activation in astrocytes and cerebral endothelial cells. Neuroscience 199:375–385PubMedPubMedCentralGoogle Scholar
  46. 46.
    Gattaz WF, Cairns NJ, Levy R, Forstl H, Braus DF, Maras A (1996) Decreased phospholipase A2 activity in the brain and in platelets of patients with Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 246:129–131PubMedGoogle Scholar
  47. 47.
    Gattaz WF, Maras A, Cairns NJ, Levy R, Forstl H (1995) Decreased phospholipase A2 activity in Alzheimer brains. Biol Psychiatry 37:13–17PubMedGoogle Scholar
  48. 48.
    Ross BM, Moszczynska A, Erlich J, Kish SJ (1998) Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem 70:786–793PubMedGoogle Scholar
  49. 49.
    Forlenza OV, Schaeffer EL, Gattaz WF (2007) The role of phospholipase A2 in neuronal homeostasis and memory formation: implications for the pathogenesis of Alzheimer's disease. J Neural Transm 114:231–238PubMedGoogle Scholar
  50. 50.
    Cho HW, Kim JH, Choi S, Kim HJ (2006) Phospholipase A2 is involved in muscarinic receptor-mediated sAPPalpha release independently of cyclooxygenase or lypoxygenase activity in SH-SY5Y cells. Neurosci Lett 397:214–218PubMedGoogle Scholar
  51. 51.
    Yang X, Sheng W, He Y, Cui J, Haidekker MA, Sun GY, Lee JC (2010) Secretory phospholipase A2 type III enhances alpha-secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity. J Lipid Res 51:957–966PubMedPubMedCentralGoogle Scholar
  52. 52.
    Villacara A, Spatz M, Dodson RF, Corn C, Bembry J (1989) Effect of arachidonic acid on cultured cerebromicrovascular endothelium: permeability, lipid peroxidation and membrane “fluidity”. Acta Neuropathol 78:310–316PubMedGoogle Scholar
  53. 53.
    Beck R, Bertolino S, Abbot SE, Aaronson PI, Smirnov SV (1998) Modulation of arachidonic acid release and membrane fluidity by albumin in vascular smooth muscle and endothelial cells. Circ Res 83:923–931PubMedGoogle Scholar
  54. 54.
    Fukaya T, Gondaira T, Kashiyae Y, Kotani S, Ishikura Y, Fujikawa S, Kiso Y et al (2007) Arachidonic acid preserves hippocampal neuron membrane fluidity in senescent rats. Neurobiol Aging 28:1179–1186PubMedGoogle Scholar
  55. 55.
    Eckert GP, Chang S, Eckmann J, Copanaki E, Hagl S, Hener U, Muller WE et al (2011) Liposome-incorporated DHA increases neuronal survival by enhancing non-amyloidogenic APP processing. Biochim Biophys Acta 1808:236–243PubMedGoogle Scholar
  56. 56.
    Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A 98:5815–5820PubMedPubMedCentralGoogle Scholar
  57. 57.
    von Arnim CA, von Einem B, Weber P, Wagner M, Schwanzar D, Spoelgen R, Strauss WL et al (2008) Impact of cholesterol level upon APP and BACE proximity and APP cleavage. Biochem Biophys Res Commun 370:207–212Google Scholar
  58. 58.
    Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G et al (2008) Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58:42–51PubMedPubMedCentralGoogle Scholar
  59. 59.
    Kinoshita A, Fukumoto H, Shah T, Whelan CM, Irizarry MC, Hyman BT (2003) Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci 116:3339–3346PubMedGoogle Scholar
  60. 60.
    Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, Schwille P et al (2008) Efficient inhibition of the Alzheimer's disease {beta}-secretase by membrane targeting. Science 320:520–523PubMedGoogle Scholar
  61. 61.
    Schobel S, Neumann S, Hertweck M, Dislich B, Kuhn PH, Kremmer E, Seed B et al (2008) A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein. J Biol Chem 283:14257–14268PubMedGoogle Scholar
  62. 62.
    Small SA, Gandy S (2006) Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 52:15–31PubMedGoogle Scholar
  63. 63.
    Schuchardt JP, Huss M, Stauss-Grabo M, Hahn A (2010) Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur J Pediatr 169:149–164PubMedGoogle Scholar
  64. 64.
    Dyall SC, Michael-Titus AT (2008) Neurological benefits of omega-3 fatty acids. Neuromol Med 10:219–235Google Scholar
  65. 65.
    Bazan NG, Scott BL (1990) Dietary omega-3 fatty acids and accumulation of docosahexaenoic acid in rod photoreceptor cells of the retina and at synapses. Ups J Med Sci Suppl 48:97–107PubMedGoogle Scholar
  66. 66.
    Holman RT, Johnson SB, Ogburn PL (1991) Deficiency of essential fatty acids and membrane fluidity during pregnancy and lactation. Proc Natl Acad Sci U S A 88:4835–4839PubMedPubMedCentralGoogle Scholar
  67. 67.
    Uauy R, Hoffman DR, Peirano P, Birch DG, Birch EE (2001) Essential fatty acids in visual and brain development. Lipids 36:885–895PubMedGoogle Scholar
  68. 68.
    Carrie I, Abellan Van Kan G, Rolland Y, Gillette-Guyonnet S, Vellas B (2009) PUFA for prevention and treatment of dementia? Curr Pharm Des 15:4173–4185PubMedGoogle Scholar
  69. 69.
    Horrocks LA, Farooqui AA (2004) Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fat Acids 70:361–372Google Scholar
  70. 70.
    Heinrichs SC (2010) Dietary omega-3 fatty acid supplementation for optimizing neuronal structure and function. Mol Nutr Food Res 54:447–456PubMedGoogle Scholar
  71. 71.
    Hashimoto M, Hossain S, Shimada T, Sugioka K, Yamasaki H, Fujii Y, Ishibashi Y et al (2002) Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats. J Neurochem 81:1084–1091PubMedGoogle Scholar
  72. 72.
    Khan WA, Blobe GC, Hannun YA (1995) Arachidonic acid and free fatty acids as second messengers and the role of protein kinase C. Cell Signal 7:171–184PubMedGoogle Scholar
  73. 73.
    Rapoport SI (2008) Arachidonic acid and the brain. J Nutr 138:2515–2520PubMedPubMedCentralGoogle Scholar
  74. 74.
    Leskovjan AC, Kretlow A, Miller LM (2010) Fourier transform infrared imaging showing reduced unsaturated lipid content in the hippocampus of a mouse model of Alzheimer's disease. Anal Chem 82:2711–2716PubMedPubMedCentralGoogle Scholar
  75. 75.
    Igarashi M, Ma K, Gao F, Kim HW, Rapoport SI, Rao JS (2011) Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex. J Alzheimers Dis 24:507–517PubMedPubMedCentralGoogle Scholar
  76. 76.
    Eckert GP, Lipka U, Muller WE (2013) Omega-3 fatty acids in neurodegenerative diseases: focus on mitochondria. Prostaglandins Leukot Essent Fat Acids 88:105–114Google Scholar
  77. 77.
    Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D et al (2003) Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 89:483–489PubMedGoogle Scholar
  78. 78.
    Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL et al (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63:1545–1550PubMedGoogle Scholar
  79. 79.
    Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, Chen PP et al (2009) Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29:9078–9089PubMedPubMedCentralGoogle Scholar
  80. 80.
    Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T et al (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39:168–177PubMedPubMedCentralGoogle Scholar
  81. 81.
    Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, Broersen LM et al (2009) DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33:482–498PubMedGoogle Scholar
  82. 82.
    Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, Freund-Levi Y et al (2013) Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-beta42 by human microglia and decrease inflammatory markers. J Alzheimers Dis 35:697–713PubMedGoogle Scholar
  83. 83.
    Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr, Frautschy SA et al (2005) Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 22:617–626PubMedGoogle Scholar
  84. 84.
    Pepe S (2007) Dietary polyunsaturated fatty acids and age-related membrane changes in the heart. Ann N Y Acad Sci 1114:381–388PubMedGoogle Scholar
  85. 85.
    Shaikh SR, Edidin M (2008) Polyunsaturated fatty acids and membrane organization: elucidating mechanisms to balance immunotherapy and susceptibility to infection. Chem Phys Lipids 153:24–33PubMedPubMedCentralGoogle Scholar
  86. 86.
    Aricha B, Fishov I, Cohen Z, Sikron N, Pesakhov S, Khozin-Goldberg I, Dagan R et al (2004) Differences in membrane fluidity and fatty acid composition between phenotypic variants of Streptococcus pneumoniae. J Bacteriol 186:4638–4644PubMedPubMedCentralGoogle Scholar
  87. 87.
    Cader AA, Butterfield DA, Watkins BA, Chung BH, Hennig B (1995) Electron spin resonance studies of fatty acid-induced alterations in membrane fluidity in cultured endothelial cells. Int J Biochem Cell Biol 27:665–673PubMedGoogle Scholar
  88. 88.
    Stillwell W, Shaikh SR, Zerouga M, Siddiqui R, Wassall SR (2005) Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod Nutr Dev 45:559–579PubMedGoogle Scholar
  89. 89.
    Loffhagen N, Hartig C, Babel W (2004) Pseudomonas putida NCTC 10936 balances membrane fluidity in response to physical and chemical stress by changing the saturation degree and the trans/cis ratio of fatty acids. Biosci Biotechnol Biochem 68:317–323PubMedGoogle Scholar
  90. 90.
    Zavodnik IB, Zaborowski A, Niekurzak A, Bryszewska M (1997) Effect of free fatty acids on erythrocyte morphology and membrane fluidity. Biochem Mol Biol Int 42:123–133PubMedGoogle Scholar
  91. 91.
    Hashimoto M, Hossain S, Shido O (2006) Docosahexaenoic acid but not eicosapentaenoic acid withstands dietary cholesterol-induced decreases in platelet membrane fluidity. Mol Cell Biochem 293:1–8PubMedGoogle Scholar
  92. 92.
    McLauren Dorrance A, Graham D, Dominiczak A, Fraser R (2000) Inhibition of nitric oxide synthesis increases erythrocyte membrane fluidity and unsaturated fatty acid content. Am J Hypertens 13:1194–1202PubMedGoogle Scholar
  93. 93.
    Calder PC, Yaqoob P, Harvey DJ, Watts A, Newsholme EA (1994) Incorporation of fatty acids by concanavalin A-stimulated lymphocytes and the effect on fatty acid composition and membrane fluidity. Biochem J 300(Pt 2):509–518PubMedPubMedCentralGoogle Scholar
  94. 94.
    Kitagawa S, Kotani K, Kametani F (1990) Inhibitory mechanism of cis-polyunsaturated fatty acids on platelet aggregation: the relation with their effects on Ca2+ mobilization, cyclic AMP levels and membrane fluidity. Biochim Biophys Acta 1054:114–118PubMedGoogle Scholar
  95. 95.
    Grimm MO, Haupenthal VJ, Rothhaar TL, Zimmer VC, Grosgen S, Hundsdorfer B, Lehmann J et al (2013) Effect of different phospholipids on alpha-secretase activity in the non-amyloidogenic pathway of Alzheimer's disease. Int J Mol Sci 14:5879–5898PubMedPubMedCentralGoogle Scholar
  96. 96.
    Grimm MO, Rothhaar TL, Grosgen S, Burg VK, Hundsdorfer B, Haupenthal VJ, Friess P et al (2012) Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). J Nutr Biochem 23:1214–1223PubMedGoogle Scholar
  97. 97.
    Stillwell W, Wassall SR (2003) Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 126:1–27PubMedGoogle Scholar
  98. 98.
    Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L et al (2006) Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23:563–572PubMedGoogle Scholar
  99. 99.
    Hooijmans CR, Rutters F, Dederen PJ, Gambarota G, Veltien A, van Groen T, Broersen LM et al (2007) Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol Dis 28:16–29PubMedGoogle Scholar
  100. 100.
    Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N Jr et al (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25:3032–3040PubMedGoogle Scholar
  101. 101.
    Sahlin C, Pettersson FE, Nilsson LN, Lannfelt L, Johansson AS (2007) Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci 26:882–889PubMedGoogle Scholar
  102. 102.
    Liu Y, Yang L, Conde-Knape K, Beher D, Shearman MS, Shachter NS (2004) Fatty acids increase presenilin-1 levels and [gamma]-secretase activity in PSwt-1 cells. J Lipid Res 45:2368–2376PubMedGoogle Scholar
  103. 103.
    Barenholz Y (2004) Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcell Biochem 37:167–215PubMedGoogle Scholar
  104. 104.
    Fantini J, Yahi N (2010) Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. Expert Rev Mol Med 12:e27PubMedPubMedCentralGoogle Scholar
  105. 105.
    Burns MP, Igbavboa U, Wang L, Wood WG, Duff K (2006) Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. Neuromol Med 8:319–328Google Scholar
  106. 106.
    Eckert GP, Kirsch C, Leutz S, Wood WG, Muller WE (2003) Cholesterol modulates amyloid beta-peptide's membrane interactions. Pharmacopsychiatry 36(Suppl 2):S136–S143PubMedGoogle Scholar
  107. 107.
    Eckert GP, Reik C, Muller WE (2013) Simvastatin alters membrane cholesterol distribution and beta-amyloid levels in brains of female APP751SL mice. Pharmazie 68:590–594PubMedGoogle Scholar
  108. 108.
    Arrais D, Martins J (2007) Bilayer polarity and its thermal dependency in the l(o) and l(d) phases of binary phosphatidylcholine/cholesterol mixtures. Biochim Biophys Acta 1768:2914–2922PubMedGoogle Scholar
  109. 109.
    Halling KK, Ramstedt B, Slotte JP (2008) Glycosylation induces shifts in the lateral distribution of cholesterol from ordered towards less ordered domains. Biochim Biophys Acta 1778:1100–1111PubMedGoogle Scholar
  110. 110.
    Chen Q, Amaral J, Biancani P, Behar J (1999) Excess membrane cholesterol alters human gallbladder muscle contractility and membrane fluidity. Gastroenterology 116:678–685PubMedGoogle Scholar
  111. 111.
    Dumas D, Latger V, Viriot ML, Blondel W, Stoltz JF (1999) Membrane fluidity and oxygen diffusion in cholesterol-enriched endothelial cells. Clin Hemorheol Microcirc 21:255–261PubMedGoogle Scholar
  112. 112.
    Socaciu C, Jessel R, Diehl HA (2000) Competitive carotenoid and cholesterol incorporation into liposomes: effects on membrane phase transition, fluidity, polarity and anisotropy. Chem Phys Lipids 106:79–88PubMedGoogle Scholar
  113. 113.
    Wang D, Schreurs BG (2010) Dietary cholesterol modulates the excitability of rabbit hippocampal CA1 pyramidal neurons. Neurosci Lett 479:327–331PubMedPubMedCentralGoogle Scholar
  114. 114.
    Hao M, Mukherjee S, Sun Y, Maxfield FR (2004) Effects of cholesterol depletion and increased lipid unsaturation on the properties of endocytic membranes. J Biol Chem 279:14171–14178PubMedGoogle Scholar
  115. 115.
    Burns MP, Rebeck GW (2010) Intracellular cholesterol homeostasis and amyloid precursor protein processing. Biochim Biophys Acta 1801:853–859PubMedPubMedCentralGoogle Scholar
  116. 116.
    Colell A, Fernandez A, Fernandez-Checa JC (2009) Mitochondria, cholesterol and amyloid beta peptide: a dangerous trio in Alzheimer disease. J Bioenerg Biomembr 41:417–423PubMedGoogle Scholar
  117. 117.
    Eckert GP, Kirsch C, Muller WE (2003) Brain-membrane cholesterol in Alzheimer's disease. J Nutr Health Aging 7:18–23PubMedGoogle Scholar
  118. 118.
    Grimm MO, Kuchenbecker J, Grosgen S, Burg VK, Hundsdorfer B, Rothhaar TL, Friess P et al (2011) Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J Biol Chem 286:14028–14039PubMedPubMedCentralGoogle Scholar
  119. 119.
    Kosicek M, Malnar M, Goate A, Hecimovic S (2010) Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts. Biochem Biophys Res Commun 393:404–409PubMedPubMedCentralGoogle Scholar
  120. 120.
    Luneva OG, Brazhe NA, Maksimova NV, Rodnenkov OV, Parshina EY, Bryzgalova NY, Maksimov GV et al (2007) Ion transport, membrane fluidity and haemoglobin conformation in erythrocyte from patients with cardiovascular diseases: role of augmented plasma cholesterol. Pathophysiology 14:41–46PubMedGoogle Scholar
  121. 121.
    Colell A, Garcia-Ruiz C, Lluis JM, Coll O, Mari M, Fernandez-Checa JC (2003) Cholesterol impairs the adenine nucleotide translocator-mediated mitochondrial permeability transition through altered membrane fluidity. J Biol Chem 278:33928–33935PubMedGoogle Scholar
  122. 122.
    Rog T, Stimson LM, Pasenkiewicz-Gierula M, Vattulainen I, Karttunen M (2008) Replacing the cholesterol hydroxyl group with the ketone group facilitates sterol flip-flop and promotes membrane fluidity. J Phys Chem B 112:1946–1952PubMedGoogle Scholar
  123. 123.
    Galbete JL, Martin TR, Peressini E, Modena P, Bianchi R, Forloni G (2000) Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem J 348(Pt 2):307–313PubMedPubMedCentralGoogle Scholar
  124. 124.
    Xiu J, Nordberg A, Qi X, Guan ZZ (2006) Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. Neurochem Int 49:459–465PubMedGoogle Scholar
  125. 125.
    Clement AB, Gimpl G, Behl C (2010) Oxidative stress resistance in hippocampal cells is associated with altered membrane fluidity and enhanced nonamyloidogenic cleavage of endogenous amyloid precursor protein. Free Radic Biol Med 48:1236–1241PubMedGoogle Scholar
  126. 126.
    Marquer C, Devauges V, Cossec JC, Liot G, Lecart S, Saudou F, Duyckaerts C et al (2011) Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. Faseb J 25:1295–1305PubMedGoogle Scholar
  127. 127.
    Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, Beel AJ et al (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science 336:1168–1171PubMedPubMedCentralGoogle Scholar
  128. 128.
    Buffone MG, Verstraeten SV, Calamera JC, Doncel GF (2009) High Cholesterol Content and Decreased Membrane Fluidity in Human Spermatozoa Are Associated With Protein Tyrosine Phosphorylation and Functional Deficiencies. J Androl 30:552–558PubMedGoogle Scholar
  129. 129.
    Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, Fumagalli R et al (1997) Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J 322(Pt 3):893–898PubMedPubMedCentralGoogle Scholar
  130. 130.
    Liu WW, Todd S, Coulson DT, Irvine GB, Passmore AP, McGuinness B, McConville M et al (2009) A novel reciprocal and biphasic relationship between membrane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets. J Neurochem 108:341–349PubMedGoogle Scholar
  131. 131.
    Bodovitz S, Klein WL (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271:4436–4440PubMedGoogle Scholar
  132. 132.
    Grbovic OM, Mathews PM, Jiang Y, Schmidt SD, Dinakar R, Summers-Terio NB, Ceresa BP et al (2003) Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J Biol Chem 278:31261–31268PubMedGoogle Scholar
  133. 133.
    Cossec JC, Simon A, Marquer C, Moldrich RX, Leterrier C, Rossier J, Duyckaerts C et al (2010) Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim Biophys Acta 1801:846–852PubMedGoogle Scholar
  134. 134.
    Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, Hartmann T (2002) Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci 22:1679–1689PubMedGoogle Scholar
  135. 135.
    Friedman R, Pellarin R, Caflisch A (2009) Amyloid aggregation on lipid bilayers and its impact on membrane permeability. J Mol Biol 387:407–415PubMedGoogle Scholar
  136. 136.
    Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K (2002) Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41:7385–7390PubMedGoogle Scholar
  137. 137.
    Terzi E, Holzemann G, Seelig J (1997) Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes. Biochemistry 36:14845–14852PubMedGoogle Scholar
  138. 138.
    Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C, Hall JE (2006) Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 128:637–647PubMedPubMedCentralGoogle Scholar
  139. 139.
    Buchsteiner A, Hauss T, Dante S, Dencher NA (2010) Alzheimer's disease amyloid-beta peptide analogue alters the ps-dynamics of phospholipid membranes. Biochim Biophys Acta 1798:1969–1976PubMedGoogle Scholar
  140. 140.
    Eckert GP, Wood WG, Muller WE (2010) Lipid membranes and beta-amyloid: a harmful connection. Curr Protein Pept Sci 11:319–325PubMedGoogle Scholar
  141. 141.
    Murray IV, Sindoni ME, Axelsen PH (2005) Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry 44:12606–12613PubMedPubMedCentralGoogle Scholar
  142. 142.
    Yao JK, Wengenack TM, Curran GL, Poduslo JF (2009) Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem Res 34:102–108PubMedGoogle Scholar
  143. 143.
    Williamson R, Usardi A, Hanger DP, Anderton BH (2008) Membrane-bound beta-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism. Faseb J 22:1552–1559PubMedGoogle Scholar
  144. 144.
    Ambroggio EE, Kim DH, Separovic F, Barrow CJ, Barnham KJ, Bagatolli LA, Fidelio GD (2005) Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. Biophys J 88:2706–2713PubMedPubMedCentralGoogle Scholar
  145. 145.
    Bokvist M, Lindstrom F, Watts A, Grobner G (2004) Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J Mol Biol 335:1039–1049PubMedGoogle Scholar
  146. 146.
    Lansbury PT Jr (1999) Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci U S A 96:3342–3344PubMedPubMedCentralGoogle Scholar
  147. 147.
    Nag S, Chen J, Irudayaraj J, Maiti S (2010) Measurement of the attachment and assembly of small amyloid-beta oligomers on live cell membranes at physiological concentrations using single-molecule tools. Biophys J 99:1969–1975PubMedPubMedCentralGoogle Scholar
  148. 148.
    Jang H, Zheng J, Lal R, Nussinov R (2008) New structures help the modeling of toxic amyloidbeta ion channels. Trends Biochem Sci 33:91–100PubMedGoogle Scholar
  149. 149.
    McLaurin J, Chakrabartty A (1996) Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Implications for neurotoxicity. J Biol Chem 271:26482–26489PubMedGoogle Scholar
  150. 150.
    Widenbrant MJ, Rajadas J, Sutardja C, Fuller GG (2006) Lipid-induced beta-amyloid peptide assemblage fragmentation. Biophys J 91:4071–4080PubMedPubMedCentralGoogle Scholar
  151. 151.
    Kawahara M, Arispe N, Kuroda Y, Rojas E (1997) Alzheimer's disease amyloid beta-protein forms Zn(2+)-sensitive, cation-selective channels across excised membrane patches from hypothalamic neurons. Biophys J 73:67–75PubMedPubMedCentralGoogle Scholar
  152. 152.
    Liguori N, Nerenberg PS, Head-Gordon T (2013) Embedding Abeta42 in heterogeneous membranes depends on cholesterol asymmetries. Biophys J 105:899–910PubMedPubMedCentralGoogle Scholar
  153. 153.
    Hicks JB, Lai Y, Sheng W, Yang X, Zhu D, Sun GY, Lee JC (2008) Amyloid-beta peptide induces temporal membrane biphasic changes in astrocytes through cytosolic phospholipase A2. Biochim Biophys Acta 1778:2512–2519PubMedPubMedCentralGoogle Scholar
  154. 154.
    Parasassi T, Gratton E, Yu WM, Wilson P, Levi M (1997) Two-photon fluorescence microscopy of laurdan generalized polarization domains in model and natural membranes. Biophys J 72:2413–2429PubMedPubMedCentralGoogle Scholar
  155. 155.
    Parasassi T, Di Stefano M, Ravagnan G, Sapora O, Gratton E (1992) Membrane aging during cell growth ascertained by Laurdan generalized polarization. Exp Cell Res 202:432–439PubMedGoogle Scholar
  156. 156.
    Arispe N, Pollard HB, Rojas E (1996) Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc Natl Acad Sci U S A 93:1710–1715PubMedPubMedCentralGoogle Scholar
  157. 157.
    Valincius G, Heinrich F, Budvytyte R, Vanderah DJ, McGillivray DJ, Sokolov Y, Hall JE et al (2008) Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity. Biophys J 95:4845–4861PubMedPubMedCentralGoogle Scholar
  158. 158.
    Alarcon JM, Brito JA, Hermosilla T, Atwater I, Mears D, Rojas E (2006) Ion channel formation by Alzheimer's disease amyloid beta-peptide (Abeta40) in unilamellar liposomes is determined by anionic phospholipids. Peptides 27:95–104PubMedGoogle Scholar
  159. 159.
    Arispe N, Diaz JC, Simakova O (2007) Abeta ion channels. Prospects for treating Alzheimer's disease with Abeta channel blockers. Biochim Biophys Acta 1768:1952–1965PubMedGoogle Scholar
  160. 160.
    Lal R, Lin H, Quist AP (2007) Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim Biophys Acta 1768:1966–1975PubMedPubMedCentralGoogle Scholar
  161. 161.
    Quist A, Doudevski I, Lin H, Azimova R, Ng D, Frangione B, Kagan B et al (2005) Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A 102:10427–10432PubMedPubMedCentralGoogle Scholar
  162. 162.
    Vaisid T, Kosower NS, Elkind E, Barnoy S (2008) Amyloid beta peptide toxicity in differentiated PC12 cells: calpain-calpastatin, caspase, and membrane damage. J Neurosci Res 86:2314–2325PubMedGoogle Scholar
  163. 163.
    Sepulveda FJ, Parodi J, Peoples RW, Opazo C, Aguayo LG (2010) Synaptotoxicity of Alzheimer beta amyloid can be explained by its membrane perforating property. PLoS One 5:e11820PubMedPubMedCentralGoogle Scholar
  164. 164.
    Blanchard BJ, Thomas VL, Ingram VM (2002) Mechanism of membrane depolarization caused by the Alzheimer Abeta1-42 peptide. Biochem Biophys Res Commun 293:1197–1203PubMedGoogle Scholar
  165. 165.
    Eckert GP, Wood WG, Muller WE (2001) Effects of aging and beta-amyloid on the properties of brain synaptic and mitochondrial membranes. J Neural Transm 108:1051–1064PubMedGoogle Scholar
  166. 166.
    Yip CM, Darabie AA, McLaurin J (2002) Abeta42-peptide assembly on lipid bilayers. J Mol Biol 318:97–107PubMedGoogle Scholar
  167. 167.
    Kremer JJ, Pallitto MM, Sklansky DJ, Murphy RM (2000) Correlation of beta-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 39:10309–10318PubMedGoogle Scholar
  168. 168.
    Li Y, Wang JJ, Cai JX (2007) Aniracetam restores the effects of amyloid-beta protein or ageing on membrane fluidity and intracellular calcium concentration in mice synaptosomes. J Neural Transm 114:1407–1411PubMedGoogle Scholar
  169. 169.
    Muller WE, Koch S, Eckert A, Hartmann H, Scheuer K (1995) beta-Amyloid peptide decreases membrane fluidity. Brain Res 674:133–136PubMedGoogle Scholar
  170. 170.
    Hashimoto M, Hossain S, Shimada T, Shido O (2006) Docosahexaenoic acid-induced protective effect against impaired learning in amyloid beta-infused rats is associated with increased synaptosomal membrane fluidity. Clin Exp Pharmacol Physiol 33:934–939PubMedGoogle Scholar
  171. 171.
    Wong PT, Schauerte JA, Wisser KC, Ding H, Lee EL, Steel DG, Gafni A (2009) Amyloid-beta membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity. J Mol Biol 386:81–96PubMedGoogle Scholar
  172. 172.
    Drago D, Bettella M, Bolognin S, Cendron L, Scancar J, Milacic R, Ricchelli F et al (2008) Potential pathogenic role of beta-amyloid(1-42)-aluminum complex in Alzheimer's disease. Int J Biochem Cell Biol 40:731–746PubMedGoogle Scholar
  173. 173.
    Chochina SV, Avdulov NA, Igbavboa U, Cleary JP, O'Hare EO, Wood WG (2001) Amyloid beta-peptide1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. J Lipid Res 42:1292–1297PubMedGoogle Scholar
  174. 174.
    Qi XL, Xiu J, Shan KR, Xiao Y, Gu R, Liu RY, Guan ZZ (2005) Oxidative stress induced by beta-amyloid peptide(1-42) is involved in the altered composition of cellular membrane lipids and the decreased expression of nicotinic receptors in human SH-SY5Y neuroblastoma cells. Neurochem Int 46:613–621PubMedGoogle Scholar
  175. 175.
    Murray IV, Liu L, Komatsu H, Uryu K, Xiao G, Lawson JA, Axelsen PH (2007) Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins. J Biol Chem 282:9335–9345PubMedPubMedCentralGoogle Scholar
  176. 176.
    Vestergaard MC, Morita M, Hamada T, Takagi M (2013) Membrane fusion and vesicular transformation induced by Alzheimer's amyloid beta. Biochim Biophys Acta 1828:1314–1321PubMedGoogle Scholar
  177. 177.
    Hyun DH, Mughal MR, Yang H, Lee JH, Ko EJ, Hunt ND, de Cabo R et al (2010) The plasma membrane redox system is impaired by amyloid beta-peptide and in the hippocampus and cerebral cortex of 3xTgAD mice. Exp Neurol 225:423–429PubMedPubMedCentralGoogle Scholar
  178. 178.
    Igbavboa U, Sun GY, Weisman GA, He Y, Wood WG (2009) Amyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes. Neuroscience 162:328–338PubMedPubMedCentralGoogle Scholar
  179. 179.
    Pan HJ, Wang RL, Xiao JL, Chang YJ, Cheng JY, Chen YR, Lee CH (2014) Using optical profilometry to characterize cell membrane roughness influenced by amyloid-beta 42 aggregates and electric fields. J Biomed Opt 19:011009PubMedGoogle Scholar
  180. 180.
    Minano-Molina AJ, Espana J, Martin E, Barneda-Zahonero B, Fado R, Sole M, Trullas R et al (2011) Soluble oligomers of amyloid-beta peptide disrupt membrane trafficking of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction. J Biol Chem 286:27311–27321PubMedPubMedCentralGoogle Scholar
  181. 181.
    Ji SR, Wu Y, Sui SF (2002) Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation. J Biol Chem 277:6273–6279PubMedGoogle Scholar
  182. 182.
    Curtain CC, Ali FE, Smith DG, Bush AI, Masters CL, Barnham KJ (2003) Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J Biol Chem 278:2977–2982PubMedGoogle Scholar
  183. 183.
    Kirsch C, Eckert GP, Mueller WE (2002) Cholesterol attenuates the membrane perturbing properties of beta-amyloid peptides. Amyloid 9:149–159PubMedGoogle Scholar
  184. 184.
    Avdulov NA, Chochina SV, Igbavboa U, Warden CS, Vassiliev AV, Wood WG (1997) Lipid binding to amyloid beta-peptide aggregates: preferential binding of cholesterol as compared with phosphatidylcholine and fatty acids. J Neurochem 69:1746–1752PubMedGoogle Scholar
  185. 185.
    Di Scala C, Yahi N, Lelievre C, Garmy N, Chahinian H, Fantini J (2013) Biochemical identification of a linear cholesterol-binding domain within Alzheimer's beta amyloid peptide. ACS Chem Neurosci 4:509–517PubMedPubMedCentralGoogle Scholar
  186. 186.
    Di Scala C, Troadec JD, Lelievre C, Garmy N, Fantini J, Chahinian H (2014) Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer beta-amyloid peptide. J Neurochem 128:186–195PubMedGoogle Scholar
  187. 187.
    Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, Dingwall C et al (2004) Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 167:953–960PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and Physiology, Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden
  2. 2.Department of BiochemistryUniversity of MissouriColumbiaUSA
  3. 3.Department of Pathology and Anatomical SciencesUniversity of MissouriColumbiaUSA
  4. 4.Department of PharmacologyGoethe UniversityFrankfurtGermany
  5. 5.Department of Biological EngineeringUniversity of MissouriColumbiaUSA

Personalised recommendations